1Therasse P,Arbuck SG,Eisenhauer EA,et al.New guidelines to evaluate the response to treatment in solid tumors:European Organization for Reseach and Treament of Cancer,National Cancer Institute of the Unite States,National Cancer Institute of Cana-da.J Natl Cancer Inst,2000,92(3):205-216.
2孙燕 周际昌.临床肿瘤内科学手册[M].北京：人民卫生出版社,2003.398-404.
3Hoff PM,Ansari R,Batist G,et al.Comparison of oral capectabine versus intravebous fluorouracil plus leucovorin as first line treatment in605patients with metastatic colorectal cancer:results of a randomized phaseⅢstudy.J Clin Oncol,2001,19(8):2282.
4Porschen R,Arkenau HT,Kubicka S,et al.PhaseⅢstudy of capecitabine plus oxaliplatin compared with fiuorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer:a final report of AIO Colorectal Study Group.J Clin Oncol,2007,25(27):4217-4223.
5Diaz-Rubio E,Tabernero I,Gomez-Espana A,et al.PhaseⅢstudy of capecitabine plus oxaliplatin as first-line the rapy in metastatic colorectal cancer:a final report of the Spanish Coop-erative Group for the Treatment of Digestive Tumors Trial.J Clin Oncol,2007,25(27):4224-4230.
4Chickpetty SM, Baswaraj R, Kumar GS. Development of novel combined time and pH-dependent based drug delivery systems for targeting 5-fluorouracil to the colon [J]. Curr Drug Deliv, 2011,8 (5) : 566-574.
5Jemal A, Bray F, Center MM, Ferlay J, et al. Global cancer statistics [J]. CA: A Cancer Journal for Clinicians, 2011,(61 ):69-90.
